This is a snippet of the transcript, sign up to read more.
It's somewhat difficult to determine precisely as we are one broker in this space. We're one of the largest, if not the largest. However, based on what we're placing and general market knowledge, I would estimate that the post-judgment products are in the billion-plus limits per year. It could be significantly higher in any given year. A single placement can be $300 to $400 million, which can push that up much higher.
This is a snippet of the transcript, sign up to read more.
That's why financing is important. Sometimes, people have the ability to pay that directly and it's worth it to them. Often they don't. So a lot of the time when people are placing these policies, they are at least financing the premium, but more often than not, they are financing the premium and monetizing more broadly backed by the policy. So if you get a $50 million policy and a lender looks at this and thinks, well, I have this $50 million insurance policy or $50 million that's going to come from the judgment, which will be the collateral for my loan. I don't know exactly how long it's going to take to get to the end of the case, so I have to build in headroom for interest to accrue within the insurance limits through the expected duration.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research